Ofatumumab
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Ofatumumab and local guidelines before prescribing.
Anti-CD20 antibody
Mechanism
Anti-CD20 monoclonal antibody.
Uses
Relapsing multiple sclerosis, CLL.
Dosing
No dose is given in the chapters. See the BNF.
Side effects
Injection-site reactions, infections, hypogammaglobulinaemia.
Interactions
Live vaccines contraindicated.
Contraindications and cautions
Active infection
Monitoring
Immunoglobulins
Pregnancy and breastfeeding
Avoid
Renal and hepatic impairment
No adjustment
Overdose and reversal
Supportive
Special advice
Screen for hepatitis B.
More from the textbook: uses, cautions and other points
- Ocrelizumab , ofatumumab , ublituximab | Anti-CD20 antibodies (B-cell depletion) | Infusion or injection reactions, infections, hepatitis B reactivation (screen), low immunoglobulins; ocrelizumab also for early primary progressive MS
Neurology: Anatomy, Physiology and Pharmacology - Ocrelizumab / ofatumumab | Anti-CD20; high efficacy; PPMS (ocrelizumab); HBV screening, infections, poor vaccine response.
Neurology: Multiple Sclerosis and inflammatory disease - Ofatumumab (monthly self-injection).
Neurology: Multiple Sclerosis and inflammatory disease - Uses - B-cell lymphoma and CLL, RA, ANCA vasculitis, SLE (off-label), membranous nephropathy, MS (ocrelizumab, ofatumumab), myasthenia (MuSK), ITP, autoimmune haemolysis, pemphigus, cryoglobulinaemia, IgG4-RD.
Clinical Immunology: Biologics, immunotherapy, checkpoint toxicity and transplant immunology